Document is current
Any future updates will be listed below
-
Authors
Luebeck, Jens https://orcid.org/0000-0003-4391-979X
Ng, Alvin Wei Tian
Galipeau, Patricia C. https://orcid.org/0000-0001-7961-7430
Li, Xiaohong https://orcid.org/0000-0003-4438-2664
Sanchez, Carissa A.
Katz-Summercorn, Annalise C.
Kim, Hoon
Jammula, Sriganesh
He, Yudou
Lippman, Scott M.
Verhaak, Roel G. W. https://orcid.org/0000-0003-2773-0436
Maley, Carlo C. https://orcid.org/0000-0002-0745-7076
Alexandrov, Ludmil B.
Reid, Brian J.
Fitzgerald, Rebecca C.
Paulson, Thomas G.
Chang, Howard Y. https://orcid.org/0000-0002-9459-4393
Wu, Sihan https://orcid.org/0000-0001-8329-7492
Bafna, Vineet https://orcid.org/0000-0002-5810-6241
Mischel, Paul S. https://orcid.org/0000-0002-4560-2211
- License Information
-
More Information
Article History
Received: 9 September 2022
Accepted: 9 March 2023
First Online: 12 April 2023
Competing interests
: P.S.M. is a co-founder, chairs the scientific advisory board (SAB) of and has equity interest in Boundless Bio. P.S.M. is also an advisor with equity for Asteroid Therapeutics and is an advisor to Sage Therapeutics. V.B. is a co-founder, consultant, SAB member and has equity interest in Boundless Bio and Abterra, and the terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. S.W. is a member of the SAB of Dimension Genomics. H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, Cartography Bio, and Orbital Therapeutics, and is an advisor to 10X Genomics, Arsenal Biosciences, Chroma Medicine, and Spring Discovery. R.C.F. is named on patents related to Cytosponge and associated assays that were licensed to Covidien (now Medtronic). R.C.F. has founder shares (<3%) in Cyted. R.G.W.V. is a co-founder of Boundless Bio and an advisor to Stellanova Therapeutics and NeuroTrials. L.B.A. is a compensated consultant and has equity interest in io9. His spouse is an employee of Biotheranostics. L.B.A. is an inventor on the US patent 10,776,718 for source identification by non-negative matrix factorization. L.B.A. also declares provisional patent applications for ‘Clustered mutations for the treatment of cancer’ (US provisional application serial number 63/289,601) and ‘Artificial intelligence architecture for predicting cancer biomarker’ (serial number 63/269,033). S.M.L. is a co-founder of io9, and also declares a provisional patent application for ‘Methods and biomarkers in cancer’ (US provisional application serial number 114198-1160). J.L. is a part-time paid consultant for Boundless Bio, and the terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. P.S.M., V.B., J.L. and S.W. declare a patent application related to this work: ‘Methods and compositions for detecting ecDNA’ (US patent application number 17/746,748). The remaining authors declare no competing interests.
